ERBB2 and breast carcinoma: Although some data indicates that PI3K inhibitors may induce apoptosis, for example in sarcomas [28] or HER2-positive breast cancer [29], consensus is that PI3K inhibitors mostly affect cell proliferation rather than cell survival [30].